John Richard Pinion - Mar 1, 2022 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
EVP of Translational Sciences and Chief Quality Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Mar 1, 2022
Transactions value $
-$299,657
Form type
4
Date filed
3/3/2022, 05:10 PM
Previous filing
Oct 18, 2021
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale -$300K -4.5K -9.04% $66.62 45.3K Mar 1, 2022 Direct F1
transaction RARE Common Stock Award $0 +14K +30.93% $0.00 59.3K Mar 1, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RARE Stock Option (Right to Buy) Award $0 +24.9K $0.00 24.9K Mar 1, 2022 Common Stock 24.9K $67.37 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
F2 Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
F3 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F4 On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

Remarks:

EVP of Translational Sciences and Chief Quality Officer